VAR2 PHARMACEUTICALS ApS: Financial statements 2020
CVR: 34621942
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
VAR2 PHARMACEUTICALS ApS (CVR 34621942) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -3,413,013 and a net result of DKK -5,390,471 compared with DKK -6,850,804 the year before. Equity in the 2020 report amounted to DKK 42,899,999. The solvency ratio was 95.8%. The company had 8 employees in the financial year.
- Gross Profit
- DKK -3,413,013
- Profit/Loss
- DKK -5,390,471
- Equity
- DKK 42,899,999
- Total Assets
- DKK 44,763,250
- Employees
- 8
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -3.4 mio. | -5.4 mio. | 42.9 mio. | 8 |
| 2019 | - | -4.7 mio. | -6.9 mio. | 48.3 mio. | 8 |
| 2018 | - | -1.9 mio. | -4 mio. | 55.1 mio. | 6 |
| 2017 | - | -4 mio. | -4.4 mio. | 13.7 mio. | 3 |
| 2016 | - | -1.6 mio. | -1.9 mio. | 9.9 mio. | - |
Official annual report
How creditworthy is VAR2 PHARMACEUTICALS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
VAR2 PHARMACEUTICALS ApS has published its annual report for 2019. Gross profit came to DKK -4,729,732, and the net result was DKK -6,850,804.
As of March 31, 2020, Ulf Andreas Linderoth Norlin has stepped down as director of VAR2 PHARMACEUTICALS ApS.
About VAR2 PHARMACEUTICALS ApS
VAR2 PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ali El-Salanti and Mads Daugaard. The board consists of Mads Daugaard (chair), Ali El-Salanti, Josef Rainer and Peter Schröcksnadel. The company is owned by ONCOMAL ApS and Københavns Universitet. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248.